Y-mabs therapeutics announces u.s. fda clearance of investigational new drug application for cd38-sada

Clearance of cd38-sada ind marks the second clinical development program utilizing the company's novel sada technology platform clearance of cd38-sada ind marks the second clinical development program utilizing the company's novel sada technology platform

YMAB Ratings Summary

YMAB Quant Ranking